康辰药业(603590) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was CNY 216,398,655.98, representing a year-on-year increase of 53.43%[4] - The net profit attributable to shareholders for Q3 2022 was CNY 21,632,131.06, a decrease of 41.84% compared to the same period last year[4] - The basic and diluted earnings per share for Q3 2022 were both CNY 0.1382, down 41.42% year-on-year[5] - Total operating revenue for the first three quarters of 2022 was CNY 587,989,983.65, a decrease of 1.02% compared to CNY 596,601,169.14 in the same period of 2021[18] - Net profit for the third quarter of 2022 was CNY 114,524,803.30, down 19.5% from CNY 142,273,626.25 in the same quarter of 2021[19] - Earnings per share (EPS) for the third quarter was CNY 0.6625, compared to CNY 0.8703 in the same period last year, reflecting a decline of 23.8%[20] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,350,352,713.22, a decrease of 0.62% from the end of the previous year[5] - As of September 30, 2022, the company's total assets amounted to RMB 3,350,352,713.22, a slight decrease from RMB 3,371,320,206.37 at the end of 2021[14] - The company's cash and cash equivalents decreased to RMB 526,088,665.20 from RMB 599,081,775.25 year-over-year[14] - Accounts receivable stood at RMB 212,813,423.96, down from RMB 233,989,936.89 in the previous year[14] - Inventory decreased to RMB 36,771,327.00 from RMB 47,020,733.62 year-over-year[15] - The total current liabilities include accounts payable of RMB 34,082,140.55, down from RMB 46,738,357.06[15] - The company reported a total current asset of RMB 877,523,434.86, a decrease from RMB 947,828,654.54[15] - Total liabilities decreased to CNY 204,309,057.31 from CNY 240,742,477.76, indicating a reduction of approximately 15.1%[17] - Total equity increased slightly to CNY 3,146,043,655.91 from CNY 3,130,577,728.61, showing a growth of 0.5%[17] Cash Flow - The cash flow from operating activities for the year-to-date period was CNY 131,673,194.89[4] - Cash flow from operating activities for the first three quarters was CNY 637,284,307.52, an increase of 16.6% from CNY 546,405,533.47 in the previous year[21] - The net cash flow from operating activities was ¥131,673,194.89, a significant improvement compared to a negative cash flow of ¥13,107,096.52 in the previous year[22] - Total cash inflow from investment activities was ¥197,467,082.77, down from ¥545,031,259.27 year-over-year[22] - The net cash flow from investment activities was -¥148,145,514.08, an improvement from -¥337,588,982.48 in the same quarter last year[22] - Cash flow from financing activities resulted in a net outflow of -¥56,294,706.10, compared to a net inflow of ¥190,243,324.15 in the previous year[23] - The ending balance of cash and cash equivalents was ¥522,898,916.48, down from ¥949,024,851.44 year-over-year[23] Expenses and Income - The company experienced a significant increase in management expenses by approximately CNY 5 million and R&D expenses by approximately CNY 1 million, impacting net profit[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses for the year-to-date period was CNY 55,929,753.17, down 53.48% year-on-year[4] - The company reported a decrease in other income by CNY 670,540 compared to the previous year, primarily due to reduced government subsidies[9] - Total operating costs increased to CNY 506,473,397.64, up 9.8% from CNY 461,334,304.84 in the previous year[18] - Research and development expenses for the first three quarters were CNY 54,706,235.57, down 17.7% from CNY 66,439,112.06 in the previous year[18] - The company reported an investment income of CNY 28,272,233.60, significantly up from CNY 6,625,700.59 in the same period of 2021[18] - Other comprehensive income after tax for the third quarter was CNY -57,580,557.97, an improvement compared to CNY -184,425,114.31 in the previous year[20] Clinical Trials and Research - The company announced the approval of the ethical review for the Phase III clinical trial of Jincao Tablets on September 28, 2022[13] - The company is in discussions with Alvogen, Inc. regarding the clinical trial application for Teriparatide injection, which was withdrawn for further documentation[13] - The company plans to disclose further updates on the clinical trial progress of Jincao Tablets as it advances[13]